

# Xpovio (selinexor)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Xpovio (selinexor)	May be subject to quantity limit

## **APPROVAL CRITERIA**

Requests for Xpovio (selinexor) may be approved if the following criteria are met:

- I. Individual has a diagnosis of relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma; **AND**
- A. Individual previously received at least two prior lines of systemic therapy; **AND**
  - B. Individual must not have DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkins and non-Hodgkins lymphoma), primary mediastinal (thymic) large B-cell lymphoma (PMBL), or known central nervous system (CNS) lymphoma (NCT02227251).

### **OR**

- II. Individual has a diagnosis of relapsed or refractory multiple myeloma; **AND**
- A. Individual is using in combination with dexamethasone; **AND**
  - B. Individual previously received at least four prior lines of therapies; **AND**
  - C. Confirmation of disease refractory to all of the following:
    - 1. At least two proteasome inhibitors (for example, bortezomib, carfilzomib, or ixazomib); **AND**
    - 2. At least two immunomodulatory agents (for example, lenalidomide, pomalidomide, or thalomid); **AND**
    - 3. An anti-CD38 monoclonal antibody (for example, daratumumab);

### **OR**

- III. Individual has a diagnosis of relapsed or refractory Multiple Myeloma; **AND**
- A. Individual is using as subsequent therapy; **AND**
  - B. Individual is using in combination with bortezomib and dexamethasone; **OR**
  - C. Individual is using in combination with dexamethasone and daratumumab (Darzalex or Darzalex Faspro) (NCCN 2A); **OR**
  - D. Individual is in combination with carfilzomib (Kyprolis).

### **Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: April 6, 2023.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2021 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. April 6, 2023.
  - a. B-Cell Lymphomas. V2.2023. Revised February 8, 2023.
  - b. Multiple Myeloma. V2.2024. Revised November 1, 2023.
6. NCT02227251. U.S. National Library of Medicine, ClinicalTrials.gov website. Available at <https://clinicaltrials.gov/ct2/show/NCT02227251?term=nct02227251&draw=2&rank=1>.
7. NCT02336815. U.S. National Library of Medicine, ClinicalTrials.gov website. Available at <https://clinicaltrials.gov/ct2/show/NCT02336815?term=nct02336815&rank=1>.
8. Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Onc 2018 Mar;36(9):859-866.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.